1. People's Republic of China Stocks

  2. •

    Basic Materials

  3. •

    Chemicals
ABA Chemicals Corporation

ABA Chemicals Corporation

300261.SZ
ABA Chemicals CorporationCN flagShenzhen Stock Exchange
4.45
CNY
-0.15
- -
4.29BMarket Cap
ABA Chemicals Corporation
300261.SZ
(Shenzhen Stock Exchange)

Recent

price

4.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.32
0.37
0.39
0.54
0.89
0.81
0.83
1.41
1.87
1.73
2.09
2.17
2.1
1.34
1.26
1.37
1.34
Revenue per Share
0.07
0.07
0.06
0.06
0.09
0.08
0.02
0.09
0.17
0.08
0.17
0.19
0.21
-0.09
-0.27
-0.17
-0.23
Basic EPS, GAAP
-0.01
-0.05
-0.08
-0.16
-0.46
-0.12
-0.1
0.13
- -
-0.01
0.26
0.35
-0.11
-0.27
0.06
-0.13
-0.14
Free Cash Flow per Basic Share
0.01
0.01
0.04
0.04
0.05
0.05
0.03
0.05
0.12
0.14
0.1
0.09
0.04
0.08
0.09
0.04
0.08
Dividend per Share
0.18
0.27
0.31
0.44
0.74
0.74
0.9
1.02
1.32
1.3
1.42
1.56
1.77
1.63
1.31
1.14
1.3
Book Value per Share
0.17
0.95
0.78
0.79
1.1
0.9
1.09
1.97
1.57
1.58
1.67
1.83
2.03
1.94
1.77
1.63
1.77
Tangible Book Value per Share
574
622
765
765
588
774
800
858
964
963
957
955
955
955
955
956
952
Basic Weighted Avg Shares
184
230
301
411
526
627
662
1,208
1,806
1,664
2,003
2,072
2,001
1,279
1,202
1,307
1,275
Sales/Revenue/Turnover
26.9
21.9
15.86
12.57
13.56
14.14
4.67
9.89
13.64
13.06
12.37
12.04
14.14
-2.06
-10.66
-3.8
-8.91
Operating Margin (%)
8
10
15
21
39
48
82
91
112
120
124
131
136
138
140
146
- -
Depreciation Expense
40
44
49
44
51
61
16
73
161
82
161
182
203
-82
-258
-160
-214
Net Income, GAAP
13.72
11.94
12.5
10.51
11.35
13.08
- -
4.22
10.3
7.43
7.33
10.58
10.21
- -
- -
- -
- -
Effective Tax Rate (%)
21.53
19.28
16.38
10.69
9.6
9.76
2.45
6.06
8.9
4.91
8.04
8.78
10.14
-6.43
-21.44
-12.2
-16.82
Profit Margin (%)
22
478
409
216
-73
-117
-32
619
293
191
345
458
584
188
-28
-222
-123
Working Capital
- -
- -
- -
- -
100
110
30
109
140
61
251
243
238
144
236
190
166
LT Debt
111
599
621
636
709
756
1,052
1,952
2,079
2,078
2,164
2,288
2,510
2,428
2,144
1,986
2,138
Total Equity
28.68
11.52
6.85
6.9
7.07
6.59
- -
5.51
7.78
6.74
7.41
6.97
7.81
- -
- -
- -
- -
Return on Invested Capital (%)
32.4
29.49
24.72
14.3
9.54
7.94
- -
6.56
8.7
4.29
7.76
8.14
8.59
- -
- -
- -
- -
Return on Capital (%)
49.89
32.95
24.46
15.38
13.09
12.14
2.51
9.15
14.94
6.46
12.33
12.8
12.79
-5.07
-18.39
-13.65
-15.63
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
995
978
1,122
LT Borrowings
210
181
142
LT Finance Leases
26
26
25
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
963
963
963
Market Capitalization
6,573
6,264
6,807

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,531
1,477
1,580
Cash, Cash Equivalents & STI
376
257
353
Accounts Receivable, Net
473
527
542
Inventories
432
436
436
Total Current Liabilities
1,559
1,533
1,703
Payables & Accruals
- -
- -
- -
ST Debt
995
978
1,122
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.84%
-1.38%
-7.34%
Free Cash Flow
-339.96%
-81.1%
-323.15%
Net Income, GAAP
50.46%
11.81%
-38.1%
Sales/Revenue/Turnover
11.67%
-6.67%
8.73%
Total Cash Common Dividend
18.52%
-1.08%
-50.53%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
220
369
351
262
1,202
2025
316
346
311
- -
1,307
2026
304
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
- -
- -
- -
-0.27
2025
-0.01
- -
- -
- -
-0.17
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.09
2025
0.01
- -
- -
- -
0.04
2026
0.01
- -
- -
- -
- -
Similar Companies
Ishan Dyes and Chemicals Ltd. (ISHANCH.NS)
Cydsa, S.A.B. de C.V. (CDSAF)
Nippon Shokubai Co., Ltd. (4114.T)
Shenzhen Dynanonic Co., Ltd (300769.SZ)
Evonik Industries AG (EVK.SW)
Holitech Technology Co., Ltd. (002217.SZ)
Business
ABA Chemicals Corporation (300261.SZ), founded in July 2003 and headquartered in Taicang, Jiangsu Province, China, engages in the research, development, production, and sale of fine chemicals, primarily serving the pharmaceutical, agrochemical, and nutritional health industries through its CDMO services and branded products. The company offers a broad portfolio of plant protection products including advanced pesticide intermediates, original drugs, preparations, plant growth regulators, herbicides, insecticides, and bactericides; pharmaceutical products encompassing intermediates, active pharmaceutical ingredients such as Levetiracetam, unnatural amino acids, pyrazoles, triazoles, azaindoles, indoles, aza-indoles, azetidines, and key intermediates like 6,6-Dimethyl-3-Azabicyclo[3.1.0]Hexane for Boceprevir and 2-chloro-1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-ethanone for Nebivolol; and nutritional health products such as NMN and AKG targeted at elderly, women, and children segments, distributed via e-commerce platforms including Tmall, Pinduoduo, JD, and Little Red Book. ABA operates seven production bases across China in locations including Taicang, Nantong Rudong, Yancheng Binhai, Xiangyang, Lanzhou, and Shangyu, plus a European base in Malta; three R&D centers anchored by Shanghai Zhangjiang Innovation Center (over 6,000 square meters), Puyi Chemical, and Yihui Biology; and maintains strategic partnerships with multinational firms such as Corteva (Kodiva), Bayer, Formis, Roche, Adimab (Aberdeen), Novartis, Teva, Daiichi Sankyo, and Sumitomo Chemical. Restructured as a joint stock limited company in February 2010 and listed on the Shenzhen Stock Exchange Growth Enterprise Market in September 2011 with registered capital of 963 million yuan, the company holds 132 domestic patents (66 invention patents) and 7 international patents, emphasizing chiral chemistry, heterocyclic chemistry, biocatalysis, continuous flow technology, and sustainable ESG practices validated by SBTi targets and Wind China Listed Companies ESG Top 100 inclusion. Recent developments include the August 2025 strategic partnership with Hengrui Pharma to advance pharmaceutical supply chain innovation and mutual growth; completion of the Yancheng Binhai South Area production facility in December 2024; trial production launch of a 2,000-ton chlorantraniliprole technical project; opening of a new R&D building in October 2024; ESG rating upgrade from BBB to AA by Wind in July 2025 (ranking 17th among 517 chemical peers and 4th in pesticides); establishment of a Lanzhou CPC branch and C93 workshop pilot in September and October 2025; and termination of certain Nantong projects and Gansu Haotian investment in 2024-2025 to realign with its customer-centric "2+X" strategy.